Laura Delgado-Ortiz, Saverio Ranciati, A. Arbillaga-Etxarri, Eva Balcells, J. Buekers, H. Demeyer, Anja Frei, E. Gimeno-Santos, N. Hopkinson, Corina de Jong, Niklas Karlsson, Z. Louvaris, L. Palmerini, M. I. Polkey, M. Puhan, Roberto A. Rabinovich, Diego A. Rodríguez Chiaradia, Robert Rodriguez-Roisin, Pere Torán-Montserrat, Ioannis Vogiatzis, Henrik Watz, Thierry Troosters, J. Garcia-Aymerich
{"title":"Real-world walking cadence in people with COPD","authors":"Laura Delgado-Ortiz, Saverio Ranciati, A. Arbillaga-Etxarri, Eva Balcells, J. Buekers, H. Demeyer, Anja Frei, E. Gimeno-Santos, N. Hopkinson, Corina de Jong, Niklas Karlsson, Z. Louvaris, L. Palmerini, M. I. Polkey, M. Puhan, Roberto A. Rabinovich, Diego A. Rodríguez Chiaradia, Robert Rodriguez-Roisin, Pere Torán-Montserrat, Ioannis Vogiatzis, Henrik Watz, Thierry Troosters, J. Garcia-Aymerich","doi":"10.1183/23120541.00673-2023","DOIUrl":null,"url":null,"abstract":"The clinical validity of real-world walking cadence in people with chronic obstructive pulmonary disease (COPD) is unsettled. Objective: to assess the levels, variability and association with clinically relevant COPD characteristics and outcomes of real-world walking cadence.We assessed walking cadence (steps per minute during walking bouts >10 s) from 7-days accelerometer data in 593 individuals with COPD from five European countries, and clinical and functional characteristics from validated questionnaires and standardised tests. Severe exacerbations during 12-months follow-up were recorded from patient reports and medical registries.Participants were mostly male (80%) and had mean (sd) age 68 (8) years, post-bronchodilator FEV157 (19)%, and 6880 (3926) steps/day. Mean walking cadence was 88 steps/min, followed a normal distribution (sd=9), and was highly stable within-person (ICC 0.92 (95%CI 0.90–0.93)). After adjusting for age, sex, height and number of walking bouts in fractional polynomial or linear regressions, walking cadence was positively associated with FEV1,6-min walk distance, physical activity (steps/day, time in moderate-to-vigorous physical activity, vector magnitude units, walking time, intensity during locomotion), physical activity experience and health-related quality of life; and negatively associated with breathlessness and depression (all p<0.05). These associations remained after further adjustment for daily steps. In negative binomial regression adjusted for multiple confounders, walking cadence related to lower number of severe exacerbations during follow-up (IRR 0.94 per step/min, 95%CI 0.91–0.99, p=0.009).Higher real-world walking cadence is associated with better COPD status and lower severe exacerbations risk, which makes it attractive as future prognostic marker and clinical outcome.","PeriodicalId":504874,"journal":{"name":"ERJ Open Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ERJ Open Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1183/23120541.00673-2023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The clinical validity of real-world walking cadence in people with chronic obstructive pulmonary disease (COPD) is unsettled. Objective: to assess the levels, variability and association with clinically relevant COPD characteristics and outcomes of real-world walking cadence.We assessed walking cadence (steps per minute during walking bouts >10 s) from 7-days accelerometer data in 593 individuals with COPD from five European countries, and clinical and functional characteristics from validated questionnaires and standardised tests. Severe exacerbations during 12-months follow-up were recorded from patient reports and medical registries.Participants were mostly male (80%) and had mean (sd) age 68 (8) years, post-bronchodilator FEV157 (19)%, and 6880 (3926) steps/day. Mean walking cadence was 88 steps/min, followed a normal distribution (sd=9), and was highly stable within-person (ICC 0.92 (95%CI 0.90–0.93)). After adjusting for age, sex, height and number of walking bouts in fractional polynomial or linear regressions, walking cadence was positively associated with FEV1,6-min walk distance, physical activity (steps/day, time in moderate-to-vigorous physical activity, vector magnitude units, walking time, intensity during locomotion), physical activity experience and health-related quality of life; and negatively associated with breathlessness and depression (all p<0.05). These associations remained after further adjustment for daily steps. In negative binomial regression adjusted for multiple confounders, walking cadence related to lower number of severe exacerbations during follow-up (IRR 0.94 per step/min, 95%CI 0.91–0.99, p=0.009).Higher real-world walking cadence is associated with better COPD status and lower severe exacerbations risk, which makes it attractive as future prognostic marker and clinical outcome.